Braveheart Bio, Inc. (BRVE) stock
BRVENasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 10, 2026
$18.78−0.71 (-3.64%)
Close on Nov 17, 2026Market cap $1.69BP/E –Yield –
Braveheart Bio ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$30.15M | – |
| Q3 FY2025 | Sep 30, 2025 | -$59.29M | – |
See a number that looks wrong?